Abstract
Almost 50% of esophageal adenocarcinoma (EAC) patients progressed from Barrett's esophagus (BE). EAC is often diagnosed at late stages and is related to dismal prognosis. However, there are still no effective methods for stratification and therapy in BE and EAC. Two public datasets (GSE26886 and GSE37200) were analyzed to identify differentially expressed genes (DEGs) between BE and EAC. Then, a series of bioinformatics analyses were performed to explore potential biomarkers associated with BE-EAC. 27 up- and 104 down-regulated genes were observed between GSE26886 and GSE37200. The GO and KEGG enrichment analysis indicated that the DEGs were highly involved in tumorigenesis. Subsequently, Weighted Gene Co-Expression Network Analysis (WGCNA) were performed to explore the potential genes related to BE-EAC, which were validated in The Cancer Genome Atlas (TCGA) database, and 5 up-regulated genes (MYO1A, ACE2, COL1A1, LGALS4, and ADRA2A) and 3 down-regulated genes (AADAC, RAB27A, and P2RY14) were found in EAC. Meanwhile, ADRA2A and AADAC could contribute to EAC pathogenesis and progression. MYO1A, ACE2, COL1A1, LGALS4, ADRA2A, AADAC, RAB27A, and P2RY14 could be potential novel diagnostic and prognostic biomarkers in BE-EAC.
Introduction
Esophageal adenocarcinoma (EAC) is a highly aggressive cancer with a dismal five-year survival rate of less than 20%. Most cases of EAC arise from Barrett’s esophagus (BE), a condition where the normal lining of the esophagus changes due to chronic acid reflux. While BE patients undergo regular endoscopic surveillance, this process is expensive, invasive, and frequently fails to catch the transition to cancer at an early, treatable stage. The primary challenge is "stratification": identifying which BE patients are at high risk of progression. This study seeks to identify the genetic "hubs" that drive the transition from BE to EAC to serve as diagnostic tools and predictors of patient survival.
Methods and Data Integration
The researchers employed a multi-step bioinformatics pipeline to analyze transcriptomic data from three primary sources:
- GSE26886: 20 BE samples and 21 EAC samples.
- GSE37200: 31 BE samples and 15 EAC samples.
- TCGA (The Cancer Genome Atlas): 70 EAC samples and 8 normal adjacent tissue samples used for validation.
Differential Expression Analysis was performed to find genes consistently up- or down-regulated across the discovery datasets. This was followed by Functional Enrichment (GO/KEGG) to map biological pathways and Weighted Gene Co-Expression Network Analysis (WGCNA) to identify "hub genes" with high network influence. Finally, clinical correlations were established using Receiver Operating Characteristic (ROC) curves for diagnostic accuracy and Kaplan-Meier plots for survival prediction.
Key Results and Biomarker Identification
The analysis identified 131 overlapping differentially expressed genes (27 up-regulated and 104 down-regulated) across the discovery datasets. The down-regulated genes in EAC were heavily involved in digestion and monocarboxylic acid metabolism, suggesting that as cells become cancerous, they lose specialized esophageal functions in favor of proliferation.
Through WGCNA and TCGA validation, the study narrowed thousands of genes down to eight "hub" biomarkers:
- Up-regulated: MYO1A, ACE2, COL1A1, LGALS4, ADRA2A
- Down-regulated: AADAC, RAB27A, P2RY14
These hub genes showed strong diagnostic performance in the TCGA cohort, with Area Under the Curve (AUC) values ranging from 0.716 to 0.861. Notably, ACE2—the receptor for SARS-CoV-2—was significantly up-regulated, adding to evidence of its aberrant role in various cancers.
Clinical Significance
While all eight genes showed diagnostic potential, ADRA2A and AADAC stood out as key prognostic markers. Statistical analysis (p < 0.05) confirmed that low expression of ADRA2A was linked to poor overall survival, while low AADAC expression correlated with a shorter progression-free interval. These findings suggest that these specific genes could be targets for personalized therapy and better risk stratification in BE patients.
Limitations and Future Work
The authors acknowledge that this study is primarily in silico. While the statistical evidence across multiple datasets is robust, "wet-lab" experiments (such as qPCR or Western blots) and prospective clinical trials are necessary to confirm these genes' functions in living tissue. Furthermore, the TCGA database lacks BE samples, requiring the use of normal tissue for validation. Future research will focus on validating these eight markers in larger patient cohorts to determine if they can effectively slow the progression from Barrett’s esophagus to adenocarcinoma.
Summary updated